Core Viewpoint - Huaxi Biological (688363) reported a decline in revenue and net profit for the first three quarters of 2025, but showed signs of recovery in the third quarter with improved profitability [1] Financial Performance - For the first three quarters, the company achieved revenue of 3.163 billion yuan, a year-on-year decrease of 18.36% [1] - The net profit attributable to shareholders for the same period was 252 million yuan, down 30.29% year-on-year [1] - In the third quarter, the company recorded revenue of 903 million yuan, a year-on-year decline of 15.16% [1] - The net profit for the third quarter was 31.53 million yuan, reflecting a year-on-year increase of 55.63% [1] Operational Improvements - The company has continued the profit recovery trend established in the second quarter, achieving year-on-year improvements for two consecutive quarters [1] - The management team, led by the chairman and general manager, has returned to frontline operations since March, implementing systematic adjustments in business philosophy, direction, and talent organization [1] - These efforts have contributed to a significant improvement in operational quality and profitability [1]